Antiviral drug treatment for emerging swine flu

Clinica Terapeutica

Volumn 160, Issue 3, 2009, Pages 243-245

  Wiwanitkit, Viroj ^a,b  

^a WIWANITKIT HOUSE   (Thailand)

^b NONE   (Thailand)

Author keywords

Antiviral drug; Swine flu; Treatment

Indexed keywords

AMANTADINE; ANTIVIRUS AGENT; OSELTAMIVIR; RIMANTADINE; ZANAMIVIR;

ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; AVIAN INFLUENZA; CLINICAL PRACTICE; DRUG BINDING; DRUG UTILIZATION; HUMAN; IMMUNE RESPONSE; INFECTION PREVENTION; INFLUENZA; INFLUENZA VIRUS A H1N1; NONHUMAN; REVIEW; SWINE INFLUENZA; UNSPECIFIED SIDE EFFECT; VIRUS PATHOGENESIS;

ANTIVIRAL AGENTS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN;

EID: 67749110178     PISSN: 00099074     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (22)

1. Cohen J. Swine flu outbreak. Past pandemics provide mixed clues to H1N1's next moves. Science 2009; 324(5930):996-7
2. Enserink M. Swine flue outbreak. Swine flu names evolving faster than swine flu itself. Science 2009; 324(5929):871
3. Novel Swine-Origin Influenza A (H1N1). Virus Investigation Team. Emergence of a Novel Swine-Origin Influenza A (H1N1) Virus in Humans. N Engl J Med 2009; May 7 (Epub ahead of print)
4. Naffakh N, van der Werf S. April 2009: An outbreak of swine-origin influenza A(H1N1) virus with evidence for human-to-human transmission. Microbes Infect 2009 May 12. (Epub ahead of print)
5. Vincent AL, Ma W, Lager KM, et al.. Swine influenza viruses a North American perspective. Adv Virus Res 2008; 72:127-54
6. Ducatez MF, Webster RG, Webby RJ. Animal influenza epidemiology. Vaccine 2008; 26 Suppl 4:D67-9
7. Shinde V, Bridges CB, Uyeki TM, et al. Triple-reassortant Swine Influenza A (H1) in humans in the United States, 2005-2009. N Engl J Med 2009; May 7 (Epub ahead of print)
8. Intharathep P, Laohpongspaisan C, Rungrotmongkol T, et al. How amantadine and rimantadine inhibit proton transport in the M2 protein channel. J Mol Graph Model 2008; 27(3):342-8
9. Monto AS. Antivirals and influenza: frequency of resistance. Pediatr Infect Dis J 2008; 27(10 Suppl):S110-2
10. Nüesch R. Antiviral treatment of influenza in humans. Ther Umsch. 2007; 64(11):635-41
11. Alves Galvão MG, Rocha Crispino Santos MA, Alves da Cunha AJ. Amantadine and rimantadine for influenza A in children and the elderly. Cochrane Database Syst Rev 2008; (1):CD002745
12. Oxford JS. Antivirals for the treatment and prevention of epidemic and pandemic influenza. Influenza Other Respir Viruses 2007; 1(1):27-34
13. Monto AS. Antivirals and influenza: frequency of resistance. Pediatr Infect Dis J 2008; 27(10 Suppl):S110-2
14. Hungnes O, Dudman SG. Resistance in influenza viruses. Tidsskr Nor Laegeforen 2008; 128(22):2601-6
15. Beigel J, Bray M. Current and future antiviral therapy of severe seasonal and avian influenza. Antiviral Res 2008; 78(1):91-102
16. Centers for Disease Control and Prevention (CDC). Update: drug susceptibility of swine-origin influenza A (H1N1) viruses, April 2009. MMWR Morbil Mortal Wkly Rep 2009; 58(16):433-5
17. Crusat M, de Jong MD. Neuraminidase inhibitors and their role in avian and pandemic influenza. Antivir Ther 2007; 12(4 Pt B):593-602
18. Reece PA. Neuraminidase inhibitor resistance in influenza viruses. J Med Virol 2007;79(10):1577-86
19. De Clercq E. Antiviral drugs in current clinical use. J Clin Virol 2004; 30(2):115-33
20. Kaji M. Neuraminidase inhibitor, anti-influenzal agent - mechanism of action, and how to use clinically. Nippon Rinsho 2003; 61(11):1975-9
21. Oseltamivir for influenza. Drug Ther Bull 2002; 40(12):89-91
22. Diepersloot RJ, Bouter KP, Hoekstra JB. Influenza infection and diabetes mellitus. Case for annual vaccination. Diabetes Care 1990; 13(8):876-82